The Evidence for Efficacy of Osteoporosis Treatment in Men with Primary Osteoporosis: A Systematic Review and Meta-Analysis of Antiresorptive and Anabolic Treatment in Men

Table 2

Baseline characteristics of included studies.

Study	Intervention (plus calcium and/or vitamin  D)		Number of patients	Age; (±SD)	BMI	BMD; (lumbar; total hip; femoral neck) in g/cm^2	BMD; (lumbar; total hip; femoral neck); T score	Duration (months)	Outcomes; measured	Lost to follow-up (intervention versus control)
Alendronate
Orwoll et al. [27]	Placebo or 10 mg/d of alendronate (500 mg/d and 400–450 IU/d)	Placebo; Alendronate	95; 146	63 (12); 63 (13)	25 (3); 25 (3)		2.2; 2.1; 2.3; 2.0; 2.1; 2.2	24	BMD	17% versus 14%
									Vertebral fractures. nonvertebral fractures (secondary endpoints)
Gonnelli et al. [28]	Placebo (calcium) or 10 mg/d of alendronate (1000 mg/d)	Placebo	38	56.6 (10.4)	24.3 (2.9)	0.737 (0.103); 0.770 (0.099); 0.632 (0.100)		36	BMD. QUS	6 versus 7
		Alendronate	39	57.2 (9.9)	24.9 (2.4)	0.725 (0.110); 0.762 (0.101); 0.622 (0.090)
Risedronate
Boonen et al. [29]	Placebo or 35 mg of risedronate (1000 mg/d and 450–500 IU/d)	Placebo	93	62 (11)	25 (4)	0.824 (0.96);	−3.1 (0.9);	24	Lumbar spine BMD; BMD at other sites. new vertebral fractures. clinical fractures (secondary endpoints)	16 versus 18
						0.763; (0.106); NA	−2.0 (0.7); NA
		Risedronate	191	60 (11)	25 (4)	0.809 (0.99);	−3.3 (0.9);
						0.768; (0.111); NA	−2.0 (0.7); NA
Ibandronate
Orwoll et al. [30]	Placebo or 150 mg Ibandronate/month	Placebo	47	65.0 (10.6)	24.8 (3.4)		−2.1 (0.68)	12	BMD	1
							−1.8 (0.70)
							−2.3 (0.55)
		Ibandronat	85	63.9 (11.2)	25.9 (4.1)		−2.1 (0.61)			3
							−1.7 (0.68)
							−2.2 (0.50)
Miacalcic
Trovas et al. [31]	Placebo or 200 IU/d of miacalcic (1000 mg/d)	Placebo	13	51.6 (10.5)	25.7 (3.1)	0.847		12	BMD	0
						(0.190); NA;
						0.753 (0.162)
		Miacalcic	15	53.3 (13.7)	26.1 (2.4)	0.866			Vertebral fractures
						(0.124); NA;
						0.737 (0.116)
Teriparatide
Trovas et al. [31]	Placebo or 20 or 40 μg Teriparatide/d versus Placebo	Placebo	147	59 (13)	25 (4)	0.85 (0.14)	−2.4 (1.2)	11	BMD	24
							−1.9 (0.8)
							−2.7 (0.8)
		Teriparatide 20 μg/d	151	59 (13)	25 (4)	0.89 (0.15)	−2.0 (1.3)			11
							−1.8 (0.8)
							−2.6 (0.8)
		Teriparatide 40 μg/d	139	58 (13)	25 (4)	0.87 (0.14)	−2.2 (1.2)			20
							−1.9 (0.9)
							−2.7 (0.8)
Orwoll et al. [32]	Placebo versus Teriparatide 32 μg	Placebo	10	54.5 (2.6)	25.9 (1.5)	0.746 (0.03)	−3.3 (0.3)	18	BMD	0
						0.781 (0.02)	−1.7 (0.2)
						0.650 (0.03)	−2.0 (0.2)
		Teriparatide	13	49.5 (2.9)	24.3 (1.0)	0.731 (0.03)	−3.5 (0.2)			0
						0.774 (0.03)	−1.7 (0.2)
						0.644 (0.02)	−1.9 (0.2)

Fx, number of patients with one or more fractures.